In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

  • STATUS
    Recruiting
  • End date
    Oct 3, 2024
  • participants needed
    16
  • sponsor
    University of Wisconsin, Madison
Updated on 3 July 2022
cancer
chronic lymphocytic leukemia
cytopenia
lymphocytosis
Accepts healthy volunteers

Summary

Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue ("Warburg effect"), therapeutic targeting of cancer metabolism has become a field of intense research effort in cancer biology.

A growing appreciation of metabolic heterogeneity and complexity is currently reshaping investigators "simplistic" understanding of metabolic reprogramming in cancer. Discovering metabolic vulnerabilities as new treatment targets for cancer requires systematic dissection of metabolic dependencies, fuel preferences, and underlying mechanisms in the specific physiological context. However, today's data on cancer cell metabolic signatures and heterogeneity in their physiological habitat of the human organism is sparse to non-existent representing a critical knowledge gap in designing effective metabolic therapies. Here, the investigators propose a "top-down" approach studying cancer cell metabolism in patients followed by mechanistic in-depth studies in cell culture and animal models to define metabolic vulnerabilities.

Investigators will develop a metabolic tracing method to quantitatively characterize metabolic signatures and fuel preferences of leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL). Isotopic metabolic tracers are nutrients that are chemically identical to the native nutrient. Incorporated stable, non-radioactive isotopes allow investigators to follow their metabolic fate by monitoring conversion of tracer nutrients into downstream metabolites using cutting-edge metabolomics analysis. Using this method, investigators propose to test the hypothesis that leukemic lymphocytes show tissue-specific metabolic preferences that differ from non-leukemic lymphocytes and that ex vivo in-plasma labeling represents a useful model for assaying metabolic activity in leukemic cells in a patient-specific manner.

Details
Condition Chronic Lymphocytic Leukemia
Treatment [U-13C]Glucose, [13C5]glutamine
Clinical Study IdentifierNCT04785989
SponsorUniversity of Wisconsin, Madison
Last Modified on3 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Group A
Adult (18 years of age or older)
No previous history of cancer
Routine history of normal blood counts and vital signs
Documented Informed Consent
Group B
Adult (18 years of age or older)
Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.)
Treatment naïve
Documented Informed Consent
Group C
Adult (18 years of age or older)
Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia
Treatment naïve
Able/willing to have bone marrow aspiration
Documented Informed Consent

Exclusion Criteria

For all participants
Prisoners
Psychiatric inpatients or people who are institutionalized
Minor (Less than 18 years of age)
History of diabetes
Cannot be on antihyperglycemic therapy
Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc
Females of child bearing potential
Persons without decision-making capacity
Person who cannot read/write English
Not meeting inclusion criteria defined above
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note